CIPHER PHARMACEUTICALS INC (CPH.CA) Stock Fundamental Analysis

Canada • Toronto Stock Exchange • TSX:CPH • CA17253X1050

14.78 CAD
+0.26 (+1.79%)
Last: Feb 4, 2026, 07:00 PM
Fundamental Rating

7

CPH gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 33 industry peers in the Pharmaceuticals industry. Both the health and profitability get an excellent rating, making CPH a very profitable company, without any liquidiy or solvency issues. CPH is not priced too expensively while it is growing strongly. Keep and eye on this one! This makes CPH very considerable for growth and quality investing!


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • In the past year CPH was profitable.
  • In the past year CPH had a positive cash flow from operations.
  • In the past 5 years CPH has always been profitable.
  • In the past 5 years CPH always reported a positive cash flow from operatings.
CPH.CA Yearly Net Income VS EBIT VS OCF VS FCFCPH.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

  • CPH has a Return On Assets of 11.77%. This is amongst the best in the industry. CPH outperforms 90.91% of its industry peers.
  • With an excellent Return On Equity value of 15.23%, CPH belongs to the best of the industry, outperforming 87.88% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 7.23%, CPH belongs to the top of the industry, outperforming 87.88% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for CPH is in line with the industry average of 8.73%.
Industry RankSector Rank
ROA 11.77%
ROE 15.23%
ROIC 7.23%
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
CPH.CA Yearly ROA, ROE, ROICCPH.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150 -200

1.3 Margins

  • CPH's Profit Margin of 34.68% is amongst the best of the industry. CPH outperforms 100.00% of its industry peers.
  • CPH's Profit Margin has improved in the last couple of years.
  • CPH has a better Operating Margin (25.51%) than 87.88% of its industry peers.
  • CPH's Operating Margin has declined in the last couple of years.
  • CPH has a better Gross Margin (74.32%) than 93.94% of its industry peers.
  • In the last couple of years the Gross Margin of CPH has declined.
Industry RankSector Rank
OM 25.51%
PM (TTM) 34.68%
GM 74.32%
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
CPH.CA Yearly Profit, Operating, Gross MarginsCPH.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • CPH has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for CPH has been increased compared to 1 year ago.
  • Compared to 5 years ago, CPH has less shares outstanding
  • The debt/assets ratio for CPH is higher compared to a year ago.
CPH.CA Yearly Shares OutstandingCPH.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
CPH.CA Yearly Total Debt VS Total AssetsCPH.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • CPH has an Altman-Z score of 6.42. This indicates that CPH is financially healthy and has little risk of bankruptcy at the moment.
  • CPH has a Altman-Z score of 6.42. This is amongst the best in the industry. CPH outperforms 90.91% of its industry peers.
  • CPH has a debt to FCF ratio of 0.45. This is a very positive value and a sign of high solvency as it would only need 0.45 years to pay back of all of its debts.
  • CPH has a better Debt to FCF ratio (0.45) than 93.94% of its industry peers.
  • CPH has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.12, CPH is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 0.45
Altman-Z 6.42
ROIC/WACC0.84
WACC8.57%
CPH.CA Yearly LT Debt VS Equity VS FCFCPH.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 1.30 indicates that CPH should not have too much problems paying its short term obligations.
  • CPH has a Current ratio of 1.30. This is in the lower half of the industry: CPH underperforms 66.67% of its industry peers.
  • CPH has a Quick Ratio of 1.30. This is a bad value and indicates that CPH is not financially healthy enough and could expect problems in meeting its short term obligations.
  • CPH's Quick ratio of 0.98 is in line compared to the rest of the industry. CPH outperforms 42.42% of its industry peers.
  • The current and quick ratio evaluation for CPH is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 1.3
Quick Ratio 0.98
CPH.CA Yearly Current Assets VS Current LiabilitesCPH.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 4.76% over the past year.
  • Measured over the past years, CPH shows a quite strong growth in Earnings Per Share. The EPS has been growing by 12.97% on average per year.
  • CPH shows a strong growth in Revenue. In the last year, the Revenue has grown by 89.17%.
  • Measured over the past years, CPH shows a quite strong growth in Revenue. The Revenue has been growing by 8.25% on average per year.
EPS 1Y (TTM)4.76%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%2000%
Revenue 1Y (TTM)89.17%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%23.75%

3.2 Future

  • Based on estimates for the next years, CPH will show a very strong growth in Earnings Per Share. The EPS will grow by 20.66% on average per year.
  • CPH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 27.91% yearly.
EPS Next Y52.6%
EPS Next 2Y-7.46%
EPS Next 3Y20.66%
EPS Next 5YN/A
Revenue Next Year50.96%
Revenue Next 2Y26.89%
Revenue Next 3Y27.91%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CPH.CA Yearly Revenue VS EstimatesCPH.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M
CPH.CA Yearly EPS VS EstimatesCPH.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 -0.5 -1

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 16.42, the valuation of CPH can be described as correct.
  • 81.82% of the companies in the same industry are more expensive than CPH, based on the Price/Earnings ratio.
  • CPH's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 28.25.
  • CPH is valuated quite expensively with a Price/Forward Earnings ratio of 27.48.
  • Based on the Price/Forward Earnings ratio, CPH is valued a bit cheaper than the industry average as 66.67% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of CPH to the average of the S&P500 Index (27.50), we can say CPH is valued inline with the index average.
Industry RankSector Rank
PE 16.42
Fwd PE 27.48
CPH.CA Price Earnings VS Forward Price EarningsCPH.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • CPH's Enterprise Value to EBITDA is on the same level as the industry average.
  • Based on the Price/Free Cash Flow ratio, CPH is valued a bit cheaper than the industry average as 78.79% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 9.18
EV/EBITDA 14.19
CPH.CA Per share dataCPH.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The excellent profitability rating of CPH may justify a higher PE ratio.
  • CPH's earnings are expected to grow with 20.66% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.31
PEG (5Y)1.27
EPS Next 2Y-7.46%
EPS Next 3Y20.66%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CPH!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CIPHER PHARMACEUTICALS INC

TSX:CPH (2/4/2026, 7:00:00 PM)

14.78

+0.26 (+1.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)03-16
Inst Owners1.29%
Inst Owner ChangeN/A
Ins Owners3.62%
Ins Owner ChangeN/A
Market Cap374.97M
Revenue(TTM)50.05M
Net Income(TTM)17.36M
Analysts80
Price Target19.58 (32.48%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.24%
Min EPS beat(2)36.14%
Max EPS beat(2)66.34%
EPS beat(4)2
Avg EPS beat(4)14.52%
Min EPS beat(4)-37.21%
Max EPS beat(4)66.34%
EPS beat(8)5
Avg EPS beat(8)34.73%
EPS beat(12)9
Avg EPS beat(12)113.55%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.76%
Min Revenue beat(2)-6.01%
Max Revenue beat(2)2.48%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-6.01%
Max Revenue beat(4)2.48%
Revenue beat(8)2
Avg Revenue beat(8)-0.16%
Revenue beat(12)3
Avg Revenue beat(12)1.53%
Revenue beat(16)3
Avg Revenue beat(16)-1.19%
PT rev (1m)6.52%
PT rev (3m)7.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.06%
EPS NY rev (1m)0.72%
EPS NY rev (3m)10.32%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.54%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.98%
Valuation
Industry RankSector Rank
PE 16.42
Fwd PE 27.48
P/S 5.49
P/FCF 9.18
P/OCF 9.16
P/B 2.41
P/tB 12.02
EV/EBITDA 14.19
EPS(TTM)0.9
EY6.09%
EPS(NY)0.54
Fwd EY3.64%
FCF(TTM)1.61
FCFY10.89%
OCF(TTM)1.61
OCFY10.92%
SpS2.69
BVpS6.13
TBVpS1.23
PEG (NY)0.31
PEG (5Y)1.27
Graham Number11.14
Profitability
Industry RankSector Rank
ROA 11.77%
ROE 15.23%
ROCE 10.05%
ROIC 7.23%
ROICexc 7.75%
ROICexgc 33.36%
OM 25.51%
PM (TTM) 34.68%
GM 74.32%
FCFM 59.76%
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
ROICexc(3y)14.84%
ROICexc(5y)25.78%
ROICexgc(3y)32.35%
ROICexgc(5y)N/A
ROCE(3y)11.69%
ROCE(5y)20.72%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-55.02%
ROICexc growth 5Y-33.6%
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
F-Score7
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 0.45
Debt/EBITDA 0.67
Cap/Depr 1.2%
Cap/Sales 0.17%
Interest Coverage 250
Cash Conversion 152.24%
Profit Quality 172.34%
Current Ratio 1.3
Quick Ratio 0.98
Altman-Z 6.42
F-Score7
WACC8.57%
ROIC/WACC0.84
Cap/Depr(3y)670.82%
Cap/Depr(5y)415.05%
Cap/Sales(3y)80.33%
Cap/Sales(5y)48.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.76%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%2000%
EPS Next Y52.6%
EPS Next 2Y-7.46%
EPS Next 3Y20.66%
EPS Next 5YN/A
Revenue 1Y (TTM)89.17%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%23.75%
Revenue Next Year50.96%
Revenue Next 2Y26.89%
Revenue Next 3Y27.91%
Revenue Next 5YN/A
EBIT growth 1Y29.19%
EBIT growth 3Y-15.61%
EBIT growth 5Y-7.36%
EBIT Next Year141.29%
EBIT Next 3Y51.03%
EBIT Next 5YN/A
FCF growth 1Y98.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y99.32%
OCF growth 3Y12.28%
OCF growth 5Y19.77%

CIPHER PHARMACEUTICALS INC / CPH.CA FAQ

What is the ChartMill fundamental rating of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?

ChartMill assigns a fundamental rating of 7 / 10 to CPH.CA.


What is the valuation status for CPH stock?

ChartMill assigns a valuation rating of 6 / 10 to CIPHER PHARMACEUTICALS INC (CPH.CA). This can be considered as Fairly Valued.


What is the profitability of CPH stock?

CIPHER PHARMACEUTICALS INC (CPH.CA) has a profitability rating of 8 / 10.


What are the PE and PB ratios of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?

The Price/Earnings (PE) ratio for CIPHER PHARMACEUTICALS INC (CPH.CA) is 16.42 and the Price/Book (PB) ratio is 2.41.


How financially healthy is CIPHER PHARMACEUTICALS INC?

The financial health rating of CIPHER PHARMACEUTICALS INC (CPH.CA) is 7 / 10.